The 2011 Fukushima nuclear disaster in Japan inflamed worldwide fears of nuclear contamination. Governments refocused attention on experimental medications to protect humans from radiation damage. U.S. biotech companies backed by grants from the Pentagon led the field. Their efforts were bogged down in promising trials with lab animals, which chronically failed in humans. Meanwhile, in Bordeaux, France, the freak discovery of a retired nuclear power worker with a suspected natural resistance to nuclear radiation offered the prospect of a dramatic breakthrough. As word of the discovery spread, danger closed in. Which competitors from as far afield as London, Tel Aviv, Tehran, and Pittsburgh were behind the abductions, thefts of scientific material, and patent disputes blocking the French effort?
About Ian Greenham
Ian Greenham was born and raised in Melbourne, Australia. After law school, he worked with one of Australia’s leading commercial law firms, specializing in trade practices and environmental protection law. Leaving the law for the country’s diplomatic service, he was in the Australian High Commission in Port Moresby soon after Papua New Guinea’s independence, when he was recruited by a major U.S. bank. Assignments over the thirty years since in Sydney, Hong Kong, London, and New York revealed the seamy side of corporate financial life that colors the gripping reality of subplots in The Fisherman’s Stamp.
Excerpt from the Book
Sophie’s car tires crunched on the gravel driveway. She eased to a stop by the front of the house. It was good to be home. Read more